Evicenter
Xarelto (rivaroxaban) in Nonvalvular atrial fibrillation
Manufacturer
Janssen Pharmaceuticals, Inc.
Prescribing information
Xarelto (opens in a new tab)
Questions
17
Last updated

All questions

Guidelines: Xarelto (rivaroxaban) in nonvalvular atrial fibrillation

2 questions · 1 source

Guidelines

Xarelto and the 2023 AF guideline: are DOACs recommended over warfarin?

Note: In the flashcard, both recommendations are Class I (Strong), Level of Evidence A (High-quality). These are class recommendations of the 2023 ACC/AHA/ACCP/HRS atrial fibrillation guideline for direct oral anticoagulants (DOACs), as reproduced in the guideline flashcard that the Xarelto HCP site links; they do not name XARELTO.

Xarelto in severe obesity: what does the 2023 AF guideline say about DOACs?

Note: In the flashcard, the first recommendation is Class 2a (Moderate), Level of Evidence B-NR, and the second Class 2b (Weak), Level of Evidence C-LD. These are class recommendations of the 2023 ACC/AHA/ACCP/HRS atrial fibrillation guideline for direct oral anticoagulants (DOACs), as reproduced in the guideline flashcard that the Xarelto HCP site links; they do not name XARELTO.